menu search

clearside biomedical announces presentations at the american academy of ophthalmology 2023 annual meeting

– Clinical Data Utilizing clearside’s Suprachoroidal Delivery Technology to be Featured in Multiple...

November 2, 2023, 11:05 am

clearside biomedical completes recruitment in odyssey phase 2b clinical trial of cls-ax in wet amd

– Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support – – Topline Data Expected in Q3 202...

November 1, 2023, 11:05 am

clearside biomedical to report third quarter 2023 financial results and provide corporate update on monday, november 13, 2023

ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) — clearside Biomedical, Inc. (Nasdaq: CLSD), a biopha...

October 31, 2023, 11:05 am

clearside biomedical positive oasis and extension study data presented at the retina society 56th annual scientific meeting

– Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – – ODYSSEY Phase 2b Clinical Trial E...

October 16, 2023, 11:05 am

clearside biomedical to participate in panel discussion at the cantor global healthcare conference

ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- clearside Biomedical, Inc. (Nasdaq: CLSD), a bioph...

September 19, 2023, 7:05 am

clearside biomedical to report second quarter 2023 financial results and provide corporate update on monday, august 14, 2023

ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- clearside Biomedical, Inc. (Nasdaq: CLSD), a biopha...

August 1, 2023, 7:05 am

clearside biomedical highlights excellent safety profile of cls-ax and potential for extended duration of effect in data presentation at the american society of retina specialists 41st annual scientif

– Suprachoroidal Injection of CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months – ALPHARETTA, Ga., July 31, 2...

July 31, 2023, 11:05 am

clearside biomedical highlights excellent safety profile of cls-ax and potential for extended duration of effect in data presentation at the american society of retina specialists 41st annual scientif

– Suprachoroidal Injection of CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months – ALPHARETTA, Ga., July 31, 2...

July 31, 2023, 11:05 am

clearside biomedical’s suprachoroidal injection platform to be featured at upcoming asrs and ois scientific meetings

– Presentations to Highlight CLS-AX as Promising Wet AMD Treatment with New Mechanism of Action and Potential for Longer Duration of Effect than Cur...

July 20, 2023, 11:05 am

clearside biomedical opens enrollment in odyssey phase 2b clinical trial of cls-ax (axitinib injectable suspension) in wet amd

– U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD – – ODYSSEY Topline Results Expected in Q3 2024 – ALPHARETTA, ...

June 1, 2023, 11:05 am

clearside biomedical announces first quarter 2023 financial results and provides corporate update

– Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 – – Positive Safety Data, Duration and Biologic Effect of C...

May 11, 2023, 11:05 am

clearside biomedical, inc. (clsd) reports q1 loss, misses revenue estimates

clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.15 per share versus the Zacks Co...

May 11, 2023, 9:56 am

clearside biomedical to participate in a fireside chat at the jmp securities life sciences conference

ALPHARETTA, Ga., May 09, 2023 (GLOBE NEWSWIRE) — clearside Biomedical, Inc. (Nasdaq: CLSD), a biophar...

May 9, 2023, 8:30 pm

clearside biomedical to report first quarter 2023 financial results and provide corporate update on thursday, may 11, 2023

ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- clearside Biomedical, Inc. (Nasdaq: CLSD), a biophar...

May 2, 2023, 7:05 am

clearside biomedical, inc. (clsd) q4 2022 earnings call transcript

clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Com...

March 9, 2023, 8:22 pm

clearside biomedical, inc. (clsd) reports q4 loss, tops revenue estimates

clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, resp...

March 9, 2023, 7:49 pm

clearside biomedical, inc. (clsd) q3 2022 earnings call transcript

clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET ...

November 9, 2022, 4:41 pm

clearside biomedical to present at the ophthalmology futures retina forum 2022

ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- clearside Biomedical, Inc. (NASDAQ:CLSD), a biophar...

August 25, 2022, 7:05 am

clearside biomedical inc (clsd) ceo george lasezkay on q2 2022 results - earnings call transcript

clearside Biomedical Inc (NASDAQ:CLSD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Comp...

August 9, 2022, 2:47 pm

clearside biomedical, inc.'s (clsd) ceo george lasezkay on q1 2022 results - earnings call transcript

clearside Biomedical, Inc. (NASDAQ:CLSD ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Comp...

May 11, 2022, 9:11 pm


Search within

Pages Search Results: